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Introduction: GTP cyclohydrolase I (GTPCH) catalyses the ﬁrst and rate-limiting reaction in the synthesis
of the enzymatic cofactor, tetrahydrobiopterin (BH4). Loss of function mutations in the GCH1 gene lead to
congenital neurological diseases such as DOPA-responsive dystonia and hyperphenylalaninemia. How-
ever, little is known about how GTPCH and BH4 affects embryonic development in utero, and in particular
whether metabolic replacement or supplementation in pregnancy is sufﬁcient to rescue genetic GTPCH
deﬁciency in the developing embryo.
Methods and results: Gch1 deﬁcient mice were generated by the insertion of loxP sites ﬂanking exons 2–3
of the Gch1 gene. Gch1ﬂ/ﬂ mice were bred with Sox2cre mice to generate mice with global Gch1
deﬁciency. Genetic ablation of Gch1 caused embryonic lethality by E13.5. Despite loss of Gch1 mRNA and
GTPCH enzymatic activity, whole embryo BH4 levels were maintained until E11.5, indicating sufﬁcient
maternal transfer of BH4 to reach this stage of development. After E11.5, Gch1/ embryos were deﬁcient
in BH4, but an unbiased metabolomic screen indicated that the lethality was not due to a gross
disturbance in metabolic proﬁle. Embryonic lethality in Gch1/ embryos was not caused by structural
abnormalities, but was associated with signiﬁcant bradycardia at E11.5. Embryonic lethality was not
rescued by maternal supplementation of BH4, but was partially rescued, up to E15.5, by maternal
supplementation of BH4 and L-DOPA.
Conclusion: These ﬁndings demonstrate a requirement for Gch1 in embryonic development and have
important implications for the understanding of pathogenesis and treatment of genetic BH4 deﬁciencies,
as well as the identiﬁcation of new potential roles for BH4.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
GTP cyclohydrolase I (GTPCH) catalyses the ﬁrst and rate-limiting
reaction in the synthesis of the enzymatic cofactor, tetrahydrobiopterin
(BH4). BH4 is essential for several enzymes with critical physiologic
and metabolic functions, including the three nitric oxide synthases
(NOS1–3; EC 1.14.13.39), the aromatic amino acid hydroxylases (phe-
nylalanine (EC 1.14.16.1), tyrosine (EC 1.14.16.2) and tryptophan (EC
1.14.16.4) hydroxylases) and alkylglycerol mono-oxygenase (AGMO;
EC 1.14.16.5) (Werner et al., 2011). Through these enzymes, BH4 is
required for nitric oxide (NO) production, phenylalanine catabolism,
synthesis of the neurotransmitters dopamine, norepinephrine, epi-
nephrine and serotonin, and for the metabolism of ether lipids.
Genetic deﬁciency in GTPCH, due to loss of function mutations in
GCH1, cause dopa-responsive dystonias and hyperphenylalaninemia,
resulting from deﬁciency in BH4. Clinically, GTPCH deﬁciency is
characterised by low levels of BH4, particularly in the cerebrospinal
ﬂuid (Furukawa et al., 1998), leading to dopamine and serotonin
depletion in the CNS, with or without hyperphenylalaninemia due to
insufﬁciency in hepatic phenylalanine metabolism (Opladen et al.,
2012). GTPCH deﬁciency can have a mild to severe phenotype and is
associated with a wide range of symptoms including muscle hypo/
hypertonia, dystonia, movement disorders without dystonia, convul-
sions and autonomic symptoms (Opladen et al., 2012). Recommen-
ded treatment strategies for patients with GTPCH deﬁciency include
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supplementation of neutrotransmitters, with L-DOPA and 5-HT, and
BH4 replacement therapy. In addition to the critical role of BH4 in
these severe genetic diseases, BH4 also plays a role in the pathogenesis
of common, acquired diseases. These include vascular disease states
such as high blood pressure, atherosclerosis and pulmonary hyperten-
sion, diabetes, neuropathic pain, depression and sickle cell disease
(Bendall et al., 2013; Costigan et al., 2012; Cunnington and Channon,
2010; Katusic et al., 2009).
Although GTPCH deﬁciencies are treatable conditions, delayed
diagnosis and treatment can result in signiﬁcant neurocognitive
impairment (Opladen et al., 2012), and early treatment does not result
in normal neurocognitive development in all patients (Ponzone et al.,
1990). A recent study suggested that prenatal treatment with L-DOPA
may improve outcomes (Brüggemann et al., 2012), indicating that
targeting BH4 deﬁciency in utero may be beneﬁcial. However, little is
known about how GTPCH and BH4 affect embryonic development in
utero, and in particular whether metabolic replacement or supple-
mentation in pregnancy is sufﬁcient to rescue genetic BH4 deﬁciency
in the developing embryo. This is a critical question to devise new
treatment strategies.
Previous studies of the importance of BH4 biosynthesis have
used systemic pharmacologic inhibitors of GTPCH (Cotton, 1986;
Mitchell et al., 2003), or the hph-1 hyperphenylalaninemic mouse,
generated by ENU mutagenesis, that has moderate systemic BH4
deﬁciency due to reduced gene expression from the GCH1 locus
(Cosentino et al., 2001; Khoo et al., 2004). However, in the hph-1
mouse, variable BH4 deﬁciency in different cell and tissue types,
and the moderate reduction in GTPCH activity, results in no gross
abnormality in foetal development or survival, and limit the
interpretation of the role in GTPCH in development (McDonald
and Bode, 1988). Indeed, no genetic mouse model has tested the
requirement for GTPCH and de novo BH4 biosynthesis in vivo. To
test this hypothesis we generated a novel mouse model with
genetic deletion of Gch1, and assessed embryonic development
and the effectiveness of metabolic supplementation during preg-
nancy to treat embryonic BH4 deﬁciency.
Materials and methods
Generation of the GCH1ﬂ/ﬂ mouse and GCH1 global knock out mouse
A plasmid containing a FRT-PGK-promoter and a neomycin-FRT-
LoxP positive selection cassette was inserted in the intron 3 sequence
of Gch1. An additional LoxP site was inserted into intron 1 to ﬂox exon
2–3. The Gch1 ﬂoxed mouse was generated using homologous re-
combination in ES cells. Two chimeric male offspring with 90–100%
chimerism were selected for breeding, with one chimera generating a
founder with germline transmission. Flp-mediated excision of the
neomycin cassette was carried out by breeding the founder male with
a Flp deleter female. These pups were further bred with C57BL6/J mice
to backcross 7, to generate pure lines of GCH1ﬂ/ﬂ mice.
In order to generate mice globally deﬁcient in BH4, we crossed
GCH1ﬂ/ﬂmicewith Sox2Cre mice. The progeny of this cross were bred
to generate mice with heterozygous deletion of Gch1 (Gch1þ /),
without either a Cre or a Gch1 ﬂoxed allele.
Timed matings and dosing studies
Timed matings were carried out using Gch1þ / male and female
mice. Identiﬁcation of a mucosal plug was considered day 0.5 gesta-
tion, embryos were harvested and either snap frozen and stored at
80 1C until analysis or processed for histological staining. Embryo-
nic yolk sacs were divided into two and the genotype of the embryos
determined by standard PCR techniques.
Gch1þ / mice were mated to generate Gch1/ , Gch1þ / and
Gch1þ /þ littermate embryos. Dams were treated with sepiapterin,
(twice daily subcutaneous dosing, 5 mg/kg in PBS) and/or L-DOPA
(drinking water, 1 mg/ml with 0.25% ascorbic acid) from E7.5 until
either E13.5 or E15.5. Embryos were harvested from sacriﬁced
dams at either E13.5 or E15.5. At harvest embryos were examined
for the presence of a heart beat and gross abnormalities.
Embryonic heart rate analysis
At E10.5 and E11.5; dams were anesthetised with isoﬂurane
(1–1.5%) in 100% oxygen and placed on a homoeothermic mat, the
abdomen was shaved and embryonic heart rates were quantiﬁed in
utero using a Visualsonics Vevo 2100 with a 22–55 MHz transducer.
Maternal body temperature was maintained between 36 and
37.5 1C and maternal heart rate was maintained between 400 and
500 bpm. An initial scan was made and a uterine map drawn of the
location of each embryo. Embryonic heart rates were measured by
counting waveforms in pulse wave Doppler mode over a 30 s
period. Embryos were harvested from the dam under general
anaesthetic and each embryo was assigned an identiﬁcation num-
ber corresponding to their location on the scan to allow for genetic
identiﬁcation of the scanned embryos.
Histology and immunohistochemistry
Embryo morphology was assessed in parafﬁn-embedded embryo
sections stained with haematoxylin and eosin (Merck, Germany).
Whole embryos were sectioned, stained and all section assessed for
abnormalities. Whole mount PECAM staining was performed on
embryos as described before (Smart et al., 2010), using rat anti-
mouse PECAM. Embryos were then subjected to DAB substrate (Vector
Labs) and cleared (50% glycerol). Histological quantiﬁcation was
carried out on digitised microscopic images using Image-Pro Plus.
RNA
Total RNA was obtained from homogenised embryos or adult
tissue by Trizol extraction. Reverse transcription was carried out
using the QuantiTect reverse transcription kit (Qiagen, UK) on 1 μg
total RNA. Quantitative real-time RT–PCR was performed with an
iCycler IQ real-time detection system (BioRad Laboratories, USA)
using primers and probes from the TaqMan Gene Expression Assay
system (Applied Biosystems, UK).
LC-MS-based Metabolomic screening
E11.5 embryos were exposed to three subsequent rounds of
homogenisation in cold (80 1C) methanol (80%) to rapidly quench
metabolism and extract small molecule metabolites. The supernatant
from each round was pooled and dried in a speed-vac. Protein assays
were carried out on the tissue pellet to allow for normalisation.
Metabolite extracts were resuspended in 70% acetonitrileþ0.2%
ammonium hydroxide to their appropriate protein concentrations.
Resuspended metabolite samples were spun to remove residual
debris, transferred to 250 mL conical polypropylene vials, capped,
and loaded into the LC autosampler for subsequent LC-MS analysis.
3 mL of each sample was injected into the LC-MS platform. Further
details regarding the LC-MS platform, data analysis and the identi-
ﬁcation of sample metabolites are described in detail within the
Supplementary Material.
BH4, Phenylalanine and catecholamine analysis
BH4 levels in embryos and adult tissue was determined by HPLC
followed by electrochemical and ﬂuorescent detection, as previously
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described (Crabtree et al., 2009). Brieﬂy, embryos were homogenised
in phosphate-buffered saline (50mM), pH 7.4, containing dithioery-
thritol (1 mM) and EDTA (100 μM), centrifuged (15 min at 13,000 rpm
and 4 1C), and the supernatant removed and the protein precipitated
with ice cold phosphoric acid (1 M), TCA (2M), and dithioerythritol
(1 mM) and centrifuged. Samples were injected onto an isocratic HPLC
system and quantiﬁed using sequential electrochemical (Dionex
Coulochem III; Thermoscientiﬁc, Buckinghamshire, UK) and ﬂuores-
cence (Jasco, Essex, UK) detection. HPLC separation was performed
using a 250-mm, ACE C-18 column (Hichrom, Berkshire, UK) and a
mobile phase comprising of sodium acetate (50 mM), citric acid
(5 mM), EDTA (48 μM), and dithioerythritol (160 μM) (pH 5.2) at a
ﬂow rate of 1.3 ml/min. Background currents of þ500 and 50 μA
were used for the detection of BH4 on electrochemical cells E1 and E2,
respectively. Quantiﬁcation of BH4 was done by comparison with
authentic external standards, processed identically.
For L-DOPA analysis, embryos were homogenised in PBS containing
0.1 M perchloric acid solution (PCA), homogenised and centrifuged
(13,000 g for 15 min at 4 1C). L-DOPA levels were quantiﬁed as
previously described (Ryan et al., 2014). Brieﬂy, samples were injected
onto an isocratic HPLC system and quantiﬁed using a Decade SDC
detector and a carbon working electrode held at þ0.7 V vs a Ag/AgCl
reference electrode (Antec). HPLC separation was performed using a
250-mm Microsorb C18 reverse-phase column (Agilent) and a mobile
phase comprising methanol (13% v/v), NaH2PO4 (120mM), EDTA
(0.8 mM), and sodium octane sulphonate (3.2 mM), pH 3.27, and the
ﬂow rate was ﬁxed at 1 ml/min. L-DOPA content was determined
relative to authentic, freshly prepared standards and normalised to
sample protein content.
For phenylalanine and tyrosine analysis embryos were homoge-
nised in PBS, deproteinated by the addition of PCA (0.6 mol/L) in a
ratio of 1:1 and centrifuged (13,000 rpm for 15 min at 4 1C). The
supernatant was injected onto a Jasco Plus HPLC system and quanti-
ﬁed using UV spectrophotometric detection (wavelength 210 nm).
HPLC separation was performed using a Aeris PEPTIDE C18 column
(3.6 mm, 1504.6 mm, Phenomenex) and a mobile phase comprising
acetonitrile (2.5%), octylamine (10 uL/L) and perchloric acid (0.8 mL/L),
pH 2, at a ﬂow rate of 0.75 ml/min. Quantiﬁcation of phenylalanine
and tyrosine was done by comparison with external standards and
normalised to sample protein content.
Measurement of GTPCH activity
GTPCH activity was assessed by the quantiﬁcation of the conver-
sion of GTP to 7,8-dihydroneopterin. Embryos and adult tissue was
homogenised in 300 ml Tris–HCl (100 mM), KCl (300 mM), EDTA
(2.5 mM), phenylmethanesulfonyl ﬂuoride (100 mM), and glycerol
(10% v/v), pH 7.8. After centrifugation (5 min at 13,000 rpm and
4 1C) the supernatant was incubated with 10 mM GTP (ﬁnal volume
300 ml) for 1 h at 37 1C. Samples, or neopterin standards, were
subsequently incubated with 10 ml HCl (1 M) and 10ml I2/KI solution
(1% w/v I in 2% KI) and incubated for 1 h. Samples were centrifuged
(2 min at 13,000 rpm) and 10 ml ascorbate (100 mM), 10 ml NaOH
(1 M), and calf intestinal alkaline phosphatase (0.32U) were added to
the supernatant (ﬁnal volume 340 ml). Samples were centrifuged and
then assessed using the biopterin electrochemical/ﬂuorescence HPLC
system detailed above.
Statistical Analysis
Data are presented as mean7SEM. Groups were compared using
the Mann-Whitney U test for non-parametric data or the Student's
two-sided t-test for parametric data. When comparing multiple
groups data were analysed by analysis of variance (ANOVA) with
Newman–Keuls post-test for parametric data or Kruskal–Wallis test
with Dunns post-test for non-parametric data. Chi Square was used to
test the differences between categorical variables. A value of Po0.05
was considered statistically signiﬁcant. Statistical analysis was carried
out using GraphPad Prism version 6 (GraphPad Software, USA).
Results
Generation of a Gch1 knock out mouse
For conditional deletion of the Gch1 gene, exons 2–3 were ﬂanked
with loxP sites, as these exons encode amino acids involve in the
GTPCH active site (Fig. 1 A and B). We ﬁrst conﬁrmed that insertion of
loxP sites in the Gch1 gene at these positions did not result in a
hypomorphic allele. There was no difference in BH4 levels between
Gch1þ /þ , Gch1 ﬂ/þ and Gch1 ﬂ/ﬂ mice in heart, liver or lung tissues,
indicating that the ﬂoxed Gch1 allele leads to normal levels of BH4
synthesis in gene-targeted mice (Supplementary Fig. 1).
In order to generate mice with global deletion of Gch1, we ﬁrst
crossed Gch1ﬂ/ﬂmice with Sox2Cre mice. Gch1þ / mice from Gch1þ /þ
x Gch1þ / matings were born in the expected ratio with no obvious
defects. Adult Gch1þ / mice had a signiﬁcant reduction in Gch1mRNA
expression in the heart compared to Gch1þ /þ littermates (Fig. 1C). As
expected, due to the decrease in mRNA expression there was a
concomitant reduction in GTPCH activity and BH4 levels in the hearts
of adult Gch1þ / mice compared with Gch1þ /þ littermates (Fig. 1D
and E). A signiﬁcant reduction in BH4 levels was also observed in the
lung and spleen of adult Gch1þ / mice compared with Gch1þ /þ
littermate controls. However, no difference was observed in liver or
plasma BH4 levels in these mice (Supplementary Fig. 2).
In order to generate homozygous Gch1 knockout mice (Gch1 /)
we mated Gch1þ / mice. However, this mating did not yield any
Gch1 / pups from more than 20 litters. To determine the onset of
embryonic lethality, embryos from Gch1þ / Gch1þ / matings were
harvested after timed matings, for genotyping and analysis. Up to
E10.5, Gch1 / embryos were present at the expected Mendelian
ratio, however, from E11.5 onwards alive Gch1 / embryos were
signiﬁcantly underrepresented. At E11.5 and E12.5 only 55% and 39% of
Gch1 / embryos were alive. By E13.5, all Gch1/ embryos were
either absent or dead and by E15.5 dead Gch1 / embryos were
under represented in the litter with only 4 Gch1 / embryos present
compared with 18 GCHþ /þ and 23 Gch1þ / embryos indicating
signiﬁcant reabsorption (Fig. 1F).
At E11.5, surviving Gch1/ embryos appeared normal with no
obvious oedema or blood spots present (Fig. 3A). There were no
differences in either crown to rump length or placenta weights of
surviving Gch1 / embryos compared with Gch1þ / or Gch1þ /þ
littermates (Fig. 3B and C).
Embryonic Gch1 deletion abolishes GTPCH activity and reduces both
BH4 and L-DOPA, but without global metabolomic derangement
Gch1 mRNA expression increased signiﬁcantly with the age of
the embryos from E9.5 to E13.5 (Fig. 2A). Gch1 / embryos had no
detectable Gch1 mRNA expression, whereas Gch1 mRNA was
maintained in Gch1þ / embryos. A signiﬁcant reduction in GTPCH
activity was observed in Gch1þ / compared to Gch1þ /þ embryos
and this was further reduced in Gch1-/- embryos to almost non-
detectable levels (Fig. 2B). Surprisingly, given the lack of GTPCH
activity in Gch1/ embryos a signiﬁcant reduction in BH4 levels
was not detected until E11.5 (Fig. 2C-E). The maintenance of
normal BH4 levels in Gch1/ embryos at E9.5–10.5 might be
indicative of maternal transfer of BH4. However, at E11.5 where
the embryo is larger, maternal transfer appears insufﬁcient to
maintain Gch1þ /þ levels of BH4 in the Gch1/ embryos.
The reduction in BH4 levels at E11.5 resulted in a concurrent
decrease in L-DOPA levels in Gch1/ embryos (Fig. 2F). There was no
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difference in phenylalanine levels between Gch1þ /þ and Gch1/
embryos (Fig. 2G), which could be due to the low expression levels of
PAH at this time point (Supplementary Fig. 2). No difference was
observed in tyrosine levels between Gch1þ /þ and Gch1 / embryos
(Fig. 2H). There was also no compensatory up regulation of mRNA of
other BH4 dependent enzymes, or critical enzymes in BH4 biosynth-
esis downstream of GTPCH (Supplementary Fig. 3).
Since BH4 is a critical co-factor for a number of important
metabolic enzymes, we next sought to determine whether global
BH4 deﬁciency altered the metabolic proﬁle of the embryos. Untar-
geted metabolomics analysis was used to compare metabolic proﬁles
between surviving E11.5 Gch1þ /þ and Gch1 / embryos. We quanti-
ﬁed the relative abundance of 590 features (metabolites) that were
detected in at least 80% of samples from either Gch1þ /þ and Gch1/
embryos. However, no signiﬁcant differences were observed in
metabolite levels between the two groups (P40.05). Furthermore,
unsupervised principal component analysis (data not shown) and
hierarchical clustering, based on these 590 compounds, did not result
in separation or clustering of the embryos by genotype (Fig. 2I).
We further analysed potential metabolomic differences between
Gch1þ /þ and Gch1/ embryos, using a curated metabolite library of
150 compounds, generated with pure chemical standards, known to
be implicated in BH4 biology and related metabolic processes. Thirty
eight of these compounds (listed in supplementary Table 1) were
observed in at least 80% of samples from at least one experimental
group. This targeted approach yielded similar results to the untargeted
metabolomics screen, with no signiﬁcant difference in any of the
observed metabolites between the two genotypes (P40.05) and no
distinct separation by genotype with unsupervised hierarchical analy-
sis (Fig. 2J). These experiments indicate that Gch1 / embryo lethality
observed at E11.5 is not due to gross disruption in metabolic pathways.
Embryonic Gch1 deletion does not cause structural developmental
defects, but results in foetal bradycardia
Since embryonic deﬁciency in Gch1 did not lead to any difference
in metabolic proﬁle at the whole embryo level, we reasoned that Gch1
deﬁciency could result in cell speciﬁc defects in tissues that require de
novo BH4 synthesis and may not be capable of BH4 uptake. As the
embryonic cardiovascular system is critical for foetal survival beyond
E9.5, we determined whether Gch1 deﬁciency leads to defects in the
cardiovascular system. At E11.5 no excessive pericardial ﬂuid was
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Gch1þ /þ and Gch1/ embryos.
G. Douglas et al. / Developmental Biology 399 (2015) 129–138134
observed in surviving Gch1/ embryos. Histological analysis con-
ﬁrmed no cardiovascular development abnormalities in the heart or
outﬂow tract and well organised trabeculas in the hearts of Gch1/
embryos, with no difference observed in trabeculated area between
the two groups (0.05670.005 vs. 0.06470.007 Gch1þ /þ vs. Gch1 / ,
po0.05; n¼5 per group). No blood pooling was observed in any
tissues, the dorsal aortas appeared normal and blood was contained
within the artery (Fig. 3A and D). Whole mount PECAM staining at
E9.5 and E10.5 did not reveal any abnormality in the embryonic
vasculature. Blood vessels of the intersomitic regions were normal and
an intact vascular network was observed in the head region of both
Gch1þ /þ and Gch1 / embryos suggesting that lack of embryonic
Gch1 did not affect vasculogenesis (Fig. 3E).
We next examined if the embryo lethality could in part be due to
an altered heart rate, as deletion of tyrosine hydroxylase which
reduces catecholamine synthesis results in embryonic bradycardia.
Conversely a deﬁciency in Gch1 may lead to an indirect failing of the
heart. We assessed heart rate in utero using ultrasound imaging and
demonstrated no difference in embryonic heart rate between Gch1þ /þ
and Gch1/ embryos at E10.5 (Fig. 4A). At E11.5, 7 out of 12 Gch1 /
embryos were already dead and the remaining alive Gch1-/- had a
signiﬁcantly decreased in heart rate compared to their Gch1þ /þ and
Gch1þ / littermates (8374 vs. 7074 in Gch1þ /þ vs. Gch1 /;
Fig. 4B).
Embryonic Gch1 deﬁciency is not rescued by maternal
supplementation with BH4
Post-natal lethality observed in other genetic models of BH4
deﬁciencies can be rescued by post-partum supplementation with
neurotransmitters and/or BH4. Accordingly, we next sought to estab-
lish whether embryonic lethality due to Gch1 deletion could be
rescued by maternal treatment with BH4 and catecholamine. L-DOPA
(10 mg/kg), administered to pregnant dams in the drinking water,
resulted in a signiﬁcant increase in embryonic L-DOPA levels in E11.5
Gch1þ /þ embryos (Fig. 5A). Maternal treatment with a BH4 precursor
sepiapterin (5 mg/kg twice daily by subcutaneous injection) signiﬁ-
cantly increased embryo BH4 levels, which peaked at 6 h and declined
back to baseline 14 h after administration (Fig. 5B). Based on these
observations, and to ensure continuous embryonic supplementation
with BH4, dams were dosed twice daily with sepiapterin until E11.5.
Quantiﬁcation of BH4 in embryos, harvested 14 h hours after maternal
BH4 injection (i.e. at trough level) conﬁrmed that BH4 levels in Gch1-/-
embryos were signiﬁcantly elevated compared with embryos from
untreated dams, and achieved levels of embryonic BH4 similar to
Gch1þ /þ embryos. Indeed, in embryos from dams treated with
sepiapterin there was no difference in whole embryo BH4 between
Gch1þ /þ , Gch1þ / or Gch1 / embryos (Fig. 5C), indicating effective
supplementation of maternal BH4 that is able to restore the biochem-
ical deﬁciency in BH4 in Gch1/ embryos.
To determine whether biochemical rescue of embryonic BH4
deﬁciency would prevent embryonic lethality due to Gch1 deletion,
we treated Gch1þ / dams, mated with Gch1þ / males, with either
L-DOPAþsepiapterin, or sepiapterin alone. Treatment with sepiapterin
alone did not result in a signiﬁcant increase in Gch1 / embryo
survival at E13.5, with only one Gch1/ embryo alive compared with
13 dead. However, supplementationwith both L-DOPA and sepiapterin
resulted in a signiﬁcant increase in embryonic survival, with 8 out of
18 Gch1/ embryos alive at E13.5, compared with no surviving
Gch1 / embryos out of 16 in control dams treated with saline
(Fig. 5D).We next tested whether the partial rescue in embryo survival
at E13.5 with sepiapterin and L-DOPA treatment would be sustained.
At E15.5 we observed some surviving Gch1 / embryos (4 alive out of
a total of 9), but in both the control and treated group Gch1/
embryos were signiﬁcantly under represented compared with the
expectedMendelian ratio, with only 4 embryos alive representing only
8% of the litter (Po0.02), indicating a signiﬁcant loss of Gch1/
embryos prior to E15.5, despite continued maternal supplementation
with sepiapterin and L-DOPA (Fig. 5E).
Discussion
In this study we report the ﬁrst gene targeted mouse model of
Gch1 deﬁciency. We show that deletion of Gch1 causes loss of
embryonic BH4 synthesis and embryonic lethality by E13.5. Further-
more, lethality cannot be rescued with BH4 supplementation, indicat-
ing a requirement for Gch1 in embryonic development. Embryonic
lethality in Gch1 deletion is not associated with any gross perturbation
in the metabolic pathways or with any gross organogenesis defects,
but causes embryonic bradycardia.
Our study provides novel insights into the role of Gch1 in develop-
ment. Clinically, loss of functionmutations in the Gch1 gene lead to rare
congenital neurological diseases such as dystonia, DOPA-responsive
dystonia and hyperphenylalaninemia. The majority of mutations are
heterozygous autosomal dominant with a smaller number of auto-
somal recessive mutations (Thöny and Blau, 2006). These disorders are
characterised by low levels of BH4 and decreased GTPCH activity
(Furukawa et al., 1998) (Opladen et al., 2012, 2011). Infants with GTPCH
deﬁciency are born normally but develop muscle hypotonia and
movement disorders usually within the ﬁrst year of life, with more
severe BH4 deﬁciency leading to symptoms at an earlier age (Opladen
et al., 2012). In our study global deﬁciency of Gch1 resulted in embryo
lethality at mid-gestation. Clinically, non-functional mutations resulting
in complete loss of BH4 synthesis have not been described, suggesting
that complete loss of Gch1 in humans is also likely to be embryonically
lethal. Unlike the eNOS KO mouse, which shows signiﬁcant growth
restriction at E17.5 (Heﬂer et al., 2001; van der Heijden et al., 2005),
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there was no difference in embryonic size or placenta weights between
Gch1 / and Gch1þ /þ littermates at E11.5, indicating that up to this
time point embryo growth was not retarded. As there were no
apparent histological differences in heart or vascular structure between
the Gch1 / and Gch1þ /þ littermates, it is unlikely the lethality was
due to structural abnormalities. Both catecholamine-deﬁcient embryos
and eNOS / embryos show signs of an altered development of the
vasculature and the myocardium, with blood congestion and thinning
of the myocardium (Thomas et al., 1995; Zhou et al., 1995) (Liu et al.,
2012). However, these defects predominantly present at E12.5, by
which time signiﬁcantly lethality in Gch1 / has already occurred.
GTPCH catalyses the ﬁrst and rate limiting step in the synthesis of
BH4, a critical co-factor for a number of important metabolic enzymes.
At E11.5 Gch1 / embryos were signiﬁcantly deﬁcient in both BH4
and L-DOPA, we hypothesise that as the embryos appeared structurally
normal that the lethality was in part due to a gross perturbation of
metabolic pathways. We used a targeted and untargeted metabolo-
mics screen approach to look for candidate pathways which may have
been altered due to Gch1 deﬁciency. Surprisingly, given the role of BH4
in multiple pathways there was no difference in the metabolic proﬁle
between Gch1 / and Gch1þ /þ littermates, suggesting that anymeta-
bolic disturbance can be effectively buffered by maternal metabolism,
and indicating that the embryonic lethality in Gch1 deﬁciency is not
due to gross alteration in metabolic pathways. Nevertheless, the
metabolic analysis carried out at the whole embryo level does not
exclude the possibility that cell or tissue speciﬁc differences in the
metabolic proﬁle may in part account for embryonic lethality.
Other mouse models with genetic deletion of the downstream
enzymes involved in the synthesis of BH4 have been previously
investigated. PTPS knockout mice are born alive with the expected
Mendelian ratio but die within 48 h of birth (Elzaouk et al., 2003;
Sumi-Ichinose et al., 2001). It had previously been thought that
there was no alternative pathway for the synthesis of BH4 in the
absence of PTPS. However, if this were true then it would be
expected that PTPS knock out mice would have the same pheno-
type as Gch1-/- mice. The ﬁnding of a more severe phenotype in
Gch1-/- mice suggests that either an alternative pathway for the
synthesis of BH4 exists, or that GTPCH has a role in embryonic
development that is independent of BH4 biosynthesis. Studies in
rats have indicated that GTPCH could act as a chaperone, and/or
interact with other proteins (Du et al., 2012), such that loss of
these functions could be a contributing mechanism to the embryo-
nic lethality of Gch1 deletion.
In Gch1þ /þ embryos Gch1 mRNA and BH4 levels were detectable
from E9.5 and increased markedly at E11.5 onwards, indicating a
growing role for BH4 as the embryo develops beyond this gestational
stage. Despite having no detectable Gch1 mRNA and minimal GTPCH
enzymatic activity, Gch1-/- mice did not become deﬁcient in BH4 until
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E11.5, and even by E11.5 the embryonic deﬁciency in BH4 was
proportionately much less than the observed loss of both Gch1
expression and GTPCH enzymatic activity. These ﬁndings support
previous indications that BH4 can cross the placenta (Thomas et al.,
1995; Vásquez-Vivar et al., 2009), and indicate that up to E10.5
maternal transfer of BH4 across the placenta is sufﬁcient to maintain
normal BH4 levels in the embryo, and beyond E10.5 remains sufﬁcient
to substantially mitigate the effects of Gch1 deletion on BH4 levels. It is
possible that BH4 has a physiological role in embryo development
before E10.5 which is masked in Gch1 / embryos by maternal
supplementation of BH4. Interestingly, the ﬁnding that sepiapterin
supplement Gch1 / embryos had whole embryo BH4 levels compar-
able to WT littermates at trough when BH4 levels in supplemented
Gch1þ /þ embryos were no different from control Gchþ /þ embryos
raises the possibility that BH4 in the Gch-/- embryos is being actively
maintained.
Since some BH4 can cross the placenta, we hypothesised that
Gch1-/- embryos could be rescued by maternal supplementation with
BH4. Indeed, administration of sepiapterin signiﬁcantly increased
embryonic BH4 such that, even at trough levels, Gch1-/- embryos
had comparable BH4 levels to those observed in WT littermates.
However, despite this biochemical restoration of BH4 levels at the level
of the whole embryo, embryonic lethality could not be rescued. It is
possible that despite reaching super-physiological levels of BH4 for at
least 6 h post-injection and maintain WT levels of BH4 in Gch1/
embryos at trough that key BH4-requiring cells in the embryo did not
reach WT levels. Additional experiments with alternative dosing
regimens may help to answer this question.
In common with previous observations in the PTPS knock out
mouse, we found no gross organ defects but a signiﬁcant brady-
cardia (Sumi-Ichinose et al., 2001), indicating that the cause of
lethality in Gch1 / embryos is physiological rather that anatomi-
cal. The observed bradycardia in Gch1 / embryos is most likely
due to a deﬁciency in catecholamines, as tyrosine hydroxylase (TH)
knockout mice (leading to deﬁcient L-DOPA, dopamine, noradrena-
line and adrenaline) also show signiﬁcant bradycardia at E12.5
(Zhou et al., 1995). In common with the PTPS knock out mice and
Gch1-/- embryos, both TH and dopamine β-hydroxylase KO embryos
show no gross organ abnormalities but display embryo lethality
between E16.5-E18.5 (Kobayashi et al., 1995; Sumi-Ichinose et al.,
2001; Thomas et al., 1995; Zhou et al., 1995). Catecholamines are
released by the embryo in response to in utero stress such as
hypoxia which acts to increase heart rate via the β-adrenergic
receptor (Portbury et al., 2003). Post-partum lethality in PTPS pups
can be rescued with BH4 and neurotransmitter replacement ther-
apy (Elzaouk et al., 2003; Sumi-Ichinose et al., 2001). Both TH and
dopamine β-hydroxylase KO embryos can be rescued to term by
maternal supplementation with L-DOPA (Zhou et al., 1995) or DOPS
(Thomas et al., 1995). In Gch1/ embryos L-DOPA levels were
signiﬁcantly decreased compared with Gch1þ /þ littermates. The
maternal supplementation of embryos observed in this study
indicates that BH4 can cross cell membrane. However, the mechan-
ism of this transport is unclear and it has yet to be established if all
cells are capable of taking up BH4 to the same extent and thus some
BH4 requiring cells may still be signiﬁcantly deﬁcient. If catechola-
mine producing cells in the embryo were unable to uptake BH4 this
would account for the failure of BH4 supplementation alone to
rescue Gch1 / embryos. At E13.5 supplementation with BH4 and
L-DOPA appeared to part rescue the Gch1/ embryos with 8/18
Gch1 / embryos alive at harvest, indicating that the lethality
observed in Gch1/ embryos was in part due to a catecholamine
deﬁciency. As dams were treated with both sepiapterin and L-DOPA
it is likely that the combination of these two agents was required
for the partial rescue, reﬂected in the slight delay in embryonic
lethality. However, unlike mice with genetic deletion of either TH
(Zhou et al., 1995) or dopamine β-hydroxylase (Thomas et al., 1995),
which were rescued to term with catecholamine supplementation,
Gch1/ embryos were signiﬁcantly underrepresented in the litter
(8% of the litter at E15.5) indicating that an additional factor other
than catecholamine deﬁciency was responsible for the lethality.
Indeed, the bradycardia observed in untreated E11.5 Gch1þ /
embryos could also be an indirect consequence of Gch1 deﬁciency
resulting from a failing heart due to an alternative consequence of
Gch1 deﬁciency.
Recently, AGMO has been identiﬁed as a BH4 dependent
enzyme. AGMO is the only enzyme known to cleave the ether
bond of alkylgycerols and lyso-alkylglycerol phospholidids, includ-
ing lyso-platelet activation factor (Watschinger et al., 2010;
Watschinger and Werner, 2013). In our study only minimal AGMO
expression was observed in Gch1þ /þ embryos up to E11.5 with a
marked increase in expression observed from E12.5, hence it is
unlikely that loss of AGMO function due to BH4 deﬁciency is the
cause of embryo lethality observed between E10.5 to E12.5 in this
study. However, further research into potential roles for AGMO in
embryo development will help to answer this question.
In conclusion, we have demonstrated a requirement for Gch1 in
embryonic development. lethality in Gch1 / embryos is not asso-
ciated with major metabolic disturbance, nor embryonic structural
abnormalities, but causes embryonic bradycardia. Gch1 deletion is not
rescued by BH4 supplementation (sepiapterin 5 mg/Kg twice daily),
and is only minimally impacted by catecholamine supplementation.
Thus, cellular requirements for Gch1 in embryonic development have
important implications for understanding the pathogenesis and treat-
ment of genetic BH4 deﬁciencies, and for identifying new potential
roles for BH4.
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